JAMP SODIUM POLYSTYRENE SULFONATE POWDER FOR SUSPENSION 1GG

Pajjiż: Singapor

Lingwa: Ingliż

Sors: HSA (Health Sciences Authority)

Ingredjent attiv:

Sodium Polystyrene Sulfonate

Disponibbli minn:

GOLDPLUS UNIVERSAL PTE LTD

Kodiċi ATC:

V03AE01

Għamla farmaċewtika:

POWDER, FOR SUSPENSION

Kompożizzjoni:

Sodium Polystyrene Sulfonate 1g/g

Rotta amministrattiva:

ORAL, RECTAL

Tip ta 'preskrizzjoni:

Prescription Only

Manifatturat minn:

Sava Healthcare Ltd

L-istatus ta 'awtorizzazzjoni:

ACTIVE

Data ta 'l-awtorizzazzjoni:

2023-06-14

Fuljett ta 'informazzjoni

INFORMATION FOR THE CONSUMER
JAMP Sodium Polystyrene Sulfonate
Powder for Suspension, 1 g / g
DESCRIPTION OF THE PRODUCT
JAMP Sodium Polystyrene Sulfonate (sodium polystyrene
sulfonate) is a golden brown, odorless fine powder with a
characteristic taste of sodium polystyrene sulfonate.
JAMP Sodium Polystyrene Sulfonate is a cation-exchange
resin prepared in the sodium phase, with an in vivo
exchange capacity of approximately 1 mmol (in vitro
approximately 3.1 mmol) of potassium per gram. The
sodium content is approximately 4.1 mmol (94.3 mg) per
gram of the drug. JAMP Sodium Polystyrene Sulfonate can
be administered either orally or as an enema.
What the medicinal ingredient is:
Sodium polystyrene sulfonate
What the non-medicinal ingredients are:
None
What dosage forms it comes in:
Powder for suspension
What it does:
Sodium polystyrene sulfonate is not absorbed from the
gastrointestinal tract. As the resin passes through the
gastrointestinal tract, the resin removes the potassium
ions by exchanging it for sodium ions. Most of this action
occurs in the large intestine, which excretes potassium
ions to a greater degree than does the small intestine.
Potassium exchange also occurs in the colon following
retention of the resin, when administered as an enema.
The efficiency of this process is limited and unpredictable.
It commonly approximates the order of 33 per cent but the
range is so large that definite indices of electrolyte
balance must be clearly monitored. Metabolic data are
unavailable.
INDICATION
JAMP Sodium Polystyrene Sulfonate is indicated for the
treatment of hyperkalemia.
CONTRAINDICATIONS
JAMP Sodium Polystyrene Sulfonate should not be
administered to patients with the following conditions:
• serum potassium <5 mmol / L
• history of hypersensitivity to polystyrene sulfonate resins
• obstructive bowel disease
JAMP Sodium Polystyrene Sulfonate should not be
administered _orally_ to neonates or in neonates with
reduced gut motility (postoperatively or drug induced).
POSSIBLE SIDE EFFECTS
Side effect

Karatteristiċi tal-prodott

JAMP Sodium Polystyrene Sulfonate
Powder for Suspension, 1 g / g
DESCRIPTION OF THE PRODUCT
JAMP Sodium Polystyrene Sulfonate (sodium polystyrene sulfonate) is a
golden brown, odorless fine powder with a
characteristic taste of sodium polystyrene sulfonate.
JAMP Sodium Polystyrene Sulfonate is a cation-exchange resin prepared
in the sodium phase, with an in vivo exchange
capacity of approximately 1 mmol (in vitro approximately 3.1 mmol) of
potassium per gram. The sodium content is
approximately 4.1 mmol (94.3 mg) per gram of the drug. JAMP Sodium
Polystyrene Sulfonate can be administered either
orally or as an enema.
What dosage forms it comes in:
Powder for suspension
ACTION
The action of this product is to partially release sodium ions from
the resin and replace them by potassium ions as the resin
passes along the intestine or is retained in the colon after
administration by enema. For the most part, this action occurs in
the large intestine which excretes potassium ions to a greater degree
than does the small intestine. The efficiency of this
process is limited and unpredictably variable. It commonly
approximates the order of 33% but the range is so large that
definitive indices of electrolyte balance must be clearly monitored.
Frequent serum potassium determinations, at least once
every 24 hours, should be done in order to adjust the individual
dosage. The action of this product can be accomplished by
either oral administration or by retention enema.
INDICATION
JAMP Sodium Polystyrene Sulfonate is indicated for the treatment of
hyperkalemia.
WARNINGS
Since the effective lowering of serum potassium with this product may
take hours to days, treatment with this drug alone
may be insufficient to rapidly correct severe hyperkalemia associated
with states of rapid tissue breakdown (e.g., burns and
renal failure) or hyperkalemia so marked as to constitute a medical
emergency. Therefore, other definitive measures,
including dialysis, should always be considered and may be imperative.
Serious potassium deficiency can